Bisphosphonate treatment and radiotherapy in metastatic breast cancer

Medical Oncology

Volumn 25, Issue 3, 2008, Pages 350-355

  Ural, A Ugur ^a   Avcu, Ferit ^a   Baran, Yusuf ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

Bisphosphonates; Breast cancer; Combination therapy; Radiotherapy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DEXAMETHASONE; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BONE MINERALIZATION; BONE PAIN; BREAST CANCER; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; METASTASIS; MONOTHERAPY; MORBIDITY; MULTIPLE MYELOMA; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; BONE TUMOR; BREAST TUMOR; FEMALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; FEMALE; HUMANS;

EID: 58149252810     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9044-4     Document Type: Review

References (47)

1. A Jemal 2005 Cancer statistics, 2005 CA Cancer J Clin 55 1 10 30
2. RE Coleman 2001 Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev. 27 3 165 76
3. M Cicek MJ Oursler 2006 Breast cancer bone metastasis and current small therapeutics Cancer Metastasis Rev. 25 4 635 44
4. H Hsu 1999 Tumour necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proc Natl Acad Sci USA. 96 7 3540 45
5. DL Lacey 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell. 93 2 165 76
6. WS Simonet 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell. 89 2 309 19
7. TA Guise 2002 Parathyroid hormone-related protein (PTHrP)(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo Bone. 30 5 670 6
8. L Pederson 1999 Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity Cancer Res. 59 22 5849 55
9. RR Mercer C Miyasaka AM Mastro 2004 Metastatic breast cancer cells suppress osteoblast adhesion and differentiation Clin Exp Metastasis. 21 5 427 35
10. AM Mastro 2004 Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation J Cell Biochem. 91 2 265 76
11. PJ Hoskin 2003 Bisphosphonates and radiation therapy for palliation of metastatic bone disease Cancer Treat Rev. 29 4 321 7
12. A Luini 2007 The evolution of the conservative approach to breast cancer Breast. 16 2 120 9
13. S Vukmirovic-Popovic 2002 Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma Bone. 31 4 529 35
14. R Krempien 2003 Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model Cancer. 98 6 1318 24
15. N Pandit-Taskar M Batraki CR Divgi 2004 Radiopharmaceutical therapy for palliation of bone pain from osseous metastases J Nucl Med. 45 8 1358 65
16. L Li M Story RJ Legerski 2001 Cellular responses to ionizing radiation damage Int J Radiat Oncol Biol Phys. 49 4 1157 62
17. PJ Hoskin HT Ford CL Harmer 1989 Hemibody irradiation (HBI) for metastatic bone pain in two histologically distinct groups of patients Clin Oncol (R Coll Radiol). 1 2 67 9
18. PJ Hoskin 1992 A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain Radiother Oncol. 23 2 74 8
19. G Arcangeli 1989 The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief Radiother Oncol. 14 2 95 101
20. PJ Hoskin 2000 Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity Lancet. 355 9213 1428 9
21. AU Ural F Avcu 2005 Evolving therapeutic role of bisphosphonates in multiple myeloma Br J Cancer. 93 2 267 8
22. M Sato 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest. 88 6 2095 105
23. JF Bukowski CC Dascher H Das 2005 Alternative bisphosphonate targets and mechanisms of action Biochem Biophys Res Commun. 328 3 746 50
24. JR Green 2002 Preclinical pharmacology of zoledronic acid Semin Oncol. 29 6 Suppl 21 3 11
25. AU Ural F Avcu 2005 Bisphosphonates may potentiate radiation effects: a new approach in cancer treatment? Biochem Biophys Res Commun. 336 2 373 4
26. X Li 2002 Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells J Biol Chem. 277 18 15309 16
27. G Carteni 2006 Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial Oncologist. 11 7 841 8
28. JJ Vinholes 1997 Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease Ann Oncol. 8 12 1243 50
29. AU Ural 2003 The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide Int J Hematol. 78 5 443 9
30. MV Dhodapkar 1998 Anti-myeloma activity of pamidronate in vivo Br J Haematol. 103 2 530 2
31. V Kunzmann 2000 Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma Blood. 96 2 384 92
32. GR Mundy T Yoneda 1998 Bisphosphonates as anticancer drugs N Engl J Med. 339 6 398 400
33. F Avcu 2005 The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane Eur J Haematol. 74 6 496 500
34. S Magnetto 1999 Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone Int J Cancer. 83 2 263 9
35. G van der Pluijm 1996 Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro J Clin Invest. 98 3 698 705
36. AU Ural 2006 In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells Breast Cancer Res. 8 4 R52
37. JK Woodward 2005 Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro Anticancer Drugs. 16 8 845 54
38. SP Jagdev 2001 The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel Br J Cancer. 84 8 1126 34
39. AU Ural F Avcu 2006 Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms? Acta Oncol. 45 4 491 2
40. E Algur RM Macklis UO Hafeli 2005 Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines Int J Radiat Oncol Biol Phys. 61 2 535 42
41. AU Ural F Avcu 2005 Radiosensitizing effect of zoledronic acid in small cell lung cancer Lung Cancer 50 2 271 2
42. B Kurdoglu 1999 Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines Clin Cancer Res. 5 9 2580 7
43. WG McKenna RJ Muschel 2003 Targeting tumor cells by enhancing radiation sensitivity Genes Chromosomes Cancer. 38 4 330 8
44. EJ Bernhard 1996 The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts Cancer Res. 56 8 1727 30
45. F Journe 2006 Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines Clin Exp Metastasis. 23 2 135 47
46. BE Hillner 2003. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 21 4042 57
47. V Kouloulias 2003 Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs Int J Radiat Oncol Biol Phys. 57 1 143 57